Generic Medicine Info
May be taken with or without food.
Cardiogenic and hypovolaemic shock, 2nd or 3rd degree atrioventricular block, sinoatrial block, sick sinus syndrome, symptomatic bradycardia and hypotension, untreated phaeochromocytoma, metabolic acidosis, severe peripheral arterial occlusive disease, severe Raynaud's syndrome, severe bronchial asthma or severe COPD, acute heart failure or during episodes of heart failure decompensation requiring IV inotropic therapy.
Special Precautions
Patient with bronchospastic disease, myasthenia gravis, Raynaud's syndrome, diabetes mellitus, Prinzmetal's angina, 1st degree atrioventricular block, peripheral arterial occlusive disease, psoriasis, hyperthyroidism, hypoglycaemia. Patients undergoing surgery involving general anaesthesia. Avoid abrupt withdrawal. Renal and hepatic impairment. Pregnancy and lactation. Monitoring Parameters Monitor ECG, heart rate and blood pressure.
Adverse Reactions
Blood and lymphatic system disorders: Agranulocytosis, thrombocytopenia. Cardiac disorders: Chest pain, bradycardia, palpitations. Eye disorders: Ocular pain, visual disturbance. Gastrointestinal disorders: Vomiting, constipation, diarrhoea, dry mouth, abdominal pain. General disorders and administration site conditions: Asthenia, fatigue. Musculoskeletal and connective tissue disorders: Gout, back pain, arthralgia. Nervous system disorders: Dizziness, headache. Psychiatric disorders: Rarely, depression, hallucinations, nightmare. Respiratory, thoracic and mediastinal disorders: Dyspnoea, rhinitis, sinusitis. Skin and subcutaneous tissue disorders: Rash, eczema, pruritus. Rarely, alopecia. Vascular disorders: Syncope, cold or numb extremities, hypotension, flushing.
Drug Interactions
May potentiate atrioventricular conduction time and may increase negative inotropic effect with class I antiarrhythmic drugs (e.g. quinidine, disopyramide, propafenone). Concomitant use with calcium antagonists (e.g. verapamil, diltiazem) may lead to atrioventricular block and profound hypotension. Concomitant catecholamine-depleting drugs (e.g. reserpine, guanethidine) may produce excessive reduction of sympathetic activity. Heart failure may worsen when given with centrally acting antihypertensives (e.g. clonidine, methyldopa). Increased risk of bradycardia with digitalis glycosides. Coadministration with rifampicin increases metabolic clearance of bisoprolol. Reduced hypotensive effect with NSAIDs.
CIMS Class
ATC Classification
C07AB07 - bisoprolol ; Belongs to the class of selective beta-blocking agents. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by CIMS based on bisoprolol from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in